Welcome to MS Views and News blog

MS Views and News, empowers those affected by Multiple Sclerosis (MS) with educational information, resources and services. Please scroll downward to find articles or videos of interest, then click to open the document or video.

Categories

Latest Blog Posts

May 2, 2026

New walking station brings gait therapy right into MS patients’ homes

  • Balance & Gait Issues
    /
  • Multiple Sclerosis
    /
WalkPort device designed to help people with mobility difficulties Written by Andrea Lobo, PhD | April 28, 2026 Medthera has launched WalkPort, a supported…
Balance & Gait Issues

May 2, 2026

Brain inflammation may help repair myelin, animal study shows

  • Myelin Repair
    /
  • Multiple Sclerosis
    /
Findings could guide future repair-focused treatments for MS Written by Marisa Wexler, MS | April 28, 2026 Brain inflammation is…
Myelin Repair

April 30, 2026

People Wait an Average of 50 Days to See a Neurologist, and People with MS Wait Even Longer: What Can We Do to Improve Access to MS Care?

  • Access to Care
    /
  • MS Views and News
    /
  • Multiple Sclerosis
    /
  • National MS Society Related
    /
April 2026 In a study of more than 20 million people signed up for insurance plans, individuals had to wait…
Access to Care

April 30, 2026

Key Findings on GLP-1 Use in MS

  • Complementary & Alternative therapies and devices for Multiple Sclerosis (MS)
    /
GLP-1 receptor agonists (e.g., Ozempic, Wegovy) show potential in multiple sclerosis (MS) as potential neuroprotective, anti-inflammatory, and weight-loss agents. Preclinical studies…
Complementary & Alternative therapies and devices for Multiple Sclerosis (MS)

April 30, 2026

Genentech’s Fenebrutinib Significantly Reduced Relapses Versus Standard of Care to Approximately One Every 17 Years in RMS

  • BTK Inhibitors
    /
  • MS Drug Therapies
    /
  • MS Research Study and Reports
    /
  • Multiple Sclerosis
    /
  ·       Late-breaking Phase III FENhance 1 and 2 study results showed superiority of investigational fenebrutinib compared to teriflunomide in…
BTK Inhibitors

April 28, 2026

Press Release: Sanofi’s Cenrifki (tolebrutinib) recommended for EU approval by the CHMP to treat secondary progressive multiple sclerosis without relapses

  • MS Drug Therapies
    /
Sanofi’s Cenrifki (tolebrutinib) recommended for EU approval by the CHMP to treat secondary progressive multiple sclerosis without relapses Paris, April…
MS Drug Therapies

April 22, 2026

This Blood Test Tracks MS Activity? (Octave Explained)

  • MSDA (Octave testing)
    /
  • MS BIOMARKERS
    /
What happens if you ignore early symptoms of multiple sclerosis? In this video, Dr. Boster shares a real patient story…
MSDA (Octave testing)

April 22, 2026

Genentech’s Fenebrutinib Significantly Reduced Relapses Versus Standard of Care to Approximately One Every 17 Years in RMS

  • BTK Inhibitors
    /
  • MS Drug Therapies
    /
  • Multiple Sclerosis
    /
Press Releases April 21, 2026 South San Francisco, CA — April 21, 2026 — Genentech, a member of the Roche…
BTK Inhibitors

April 13, 2026

Will Medicare Pay for a Mobility Scooter?

  • Accessibility
    /
  • TOOLS
    /
Key Points Does Medicare pay for mobility scooters? Yes— but only under specific conditions. Many seniors face daily struggles with…
Accessibility

April 13, 2026

Vagus nerve stimulation (VNS)

  • Mental Wellness
    /
  • Anxiety & Depression
    /
  • Anxiety & Depression
    /
Vagus nerve stimulation involves using a device to send electrical impulses to the vagus nerve. The vagus nerve is the…
Mental Wellness

Categories

Latest Blog Posts